• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Effects of Sitagliptin on Insulin and Glucagon Levels in Type 2 Diabetes Mellitus.西他列汀对2型糖尿病患者胰岛素和胰高血糖素水平的影响。
Diabetes Metab J. 2015 Aug;39(4):304-6. doi: 10.4093/dmj.2015.39.4.304.
2
Effects of 6-Month Sitagliptin Treatment on Insulin and Glucagon Responses in Korean Patients with Type 2 Diabetes Mellitus.6个月西他列汀治疗对韩国2型糖尿病患者胰岛素和胰高血糖素反应的影响。
Diabetes Metab J. 2015 Aug;39(4):335-41. doi: 10.4093/dmj.2015.39.4.335. Epub 2015 Jul 17.
3
Comparison of sitagliptin with nateglinide on postprandial glucose and related hormones in drug-naïve Japanese patients with type 2 diabetes mellitus: A pilot study.初治2型糖尿病日本患者中，西他列汀与那格列奈对餐后血糖及相关激素影响的比较：一项初步研究。
J Diabetes Investig. 2015 Sep;6(5):560-6. doi: 10.1111/jdi.12338. Epub 2015 Mar 15.
4
Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin.在接受西他列汀治疗的 2 型糖尿病患者中，早餐前给予米格列醇可增加午餐后血浆活性胰高血糖素样肽-1（GLP-1）水平。
Acta Diabetol. 2012 Jun;49(3):225-30. doi: 10.1007/s00592-011-0322-9. Epub 2011 Sep 6.
5
Sitagliptin and pioglitazone provide complementary effects on postprandial glucose and pancreatic islet cell function.西格列汀和吡格列酮对餐后血糖和胰岛细胞功能具有互补作用。
Diabetes Obes Metab. 2013 Dec;15(12):1101-10. doi: 10.1111/dom.12145. Epub 2013 Jul 19.
6
Effects of sitagliptin on blood pressure and heart rate in response to intraduodenal glucose infusion in patients with Type 2 diabetes: a potential role for glucose-dependent insulinotropic polypeptide?西他列汀对2型糖尿病患者十二指肠内输注葡萄糖后血压和心率的影响：葡萄糖依赖性促胰岛素多肽的潜在作用？
Diabet Med. 2015 May;32(5):595-600. doi: 10.1111/dme.12622. Epub 2014 Nov 11.
7
Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.2型糖尿病患者口服葡萄糖耐量试验后，单剂量口服二肽基肽酶-4抑制剂西他列汀对肠促胰岛素和血糖水平的影响。
J Clin Endocrinol Metab. 2006 Nov;91(11):4612-9. doi: 10.1210/jc.2006-1009. Epub 2006 Aug 15.
8
Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease.西他列汀慢性二肽基肽酶-4 抑制作用与 2 型糖尿病和冠心病患者的缺血性左心室功能障碍的持续保护相关：一项初步研究。
Circ Cardiovasc Imaging. 2014 Mar;7(2):274-81. doi: 10.1161/CIRCIMAGING.113.000785. Epub 2014 Feb 6.
9
Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes.西他列汀治疗对 2 型糖尿病患者低水平炎症标志物和细胞黏附分子的影响。
Metabolism. 2014 Sep;63(9):1141-8. doi: 10.1016/j.metabol.2014.06.004. Epub 2014 Jun 14.
10
Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes.西他列汀在 2 型糖尿病患者中降血糖作用的机制。
J Clin Endocrinol Metab. 2012 Aug;97(8):2818-26. doi: 10.1210/jc.2012-1205. Epub 2012 Jun 8.

引用本文的文献

1
Exploring Promising Therapies for Non-Alcoholic Fatty Liver Disease: A ClinicalTrials.gov Analysis.探索非酒精性脂肪性肝病的潜在疗法：一项ClinicalTrials.gov分析
Diabetes Metab Syndr Obes. 2024 Feb 2;17:545-561. doi: 10.2147/DMSO.S448476. eCollection 2024.
2
Sitagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with short bowel syndrome and colon in continuity: an open-label pilot study.西他列汀，一种二肽基肽酶-4 抑制剂，在短肠综合征和连续性结肠患者中的应用：一项开放标签的初步研究。
BMJ Open Gastroenterol. 2021 May;8(1). doi: 10.1136/bmjgast-2021-000604.
3
Combined treatment with a gastric inhibitory polypeptide receptor antagonist and a peptidyl peptidase-4 inhibitor improves metabolic abnormalities in diabetic mice.胃抑制肽受体拮抗剂和肽基肽酶-4 抑制剂联合治疗可改善糖尿病小鼠的代谢异常。
J Int Med Res. 2021 Jan;49(1):300060520985664. doi: 10.1177/0300060520985664.
4
Hyperglucagonemia in an animal model of insulin- deficient diabetes: what therapy can improve it?胰岛素缺乏型糖尿病动物模型中的高胰高血糖素血症：何种治疗方法可改善此状况？
Clin Diabetes Endocrinol. 2016 May 2;2:11. doi: 10.1186/s40842-016-0029-5. eCollection 2016.

本文引用的文献

1
Effects of 6-Month Sitagliptin Treatment on Insulin and Glucagon Responses in Korean Patients with Type 2 Diabetes Mellitus.6个月西他列汀治疗对韩国2型糖尿病患者胰岛素和胰高血糖素反应的影响。
Diabetes Metab J. 2015 Aug;39(4):335-41. doi: 10.4093/dmj.2015.39.4.335. Epub 2015 Jul 17.
2
Very short-term effects of the dipeptidyl peptidase-4 inhibitor sitagliptin on the secretion of insulin, glucagon, and incretin hormones in Japanese patients with type 2 diabetes mellitus: analysis of meal tolerance test data.二肽基肽酶-4抑制剂西他列汀对日本2型糖尿病患者胰岛素、胰高血糖素和肠促胰岛素分泌的极短期影响：进餐耐量试验数据分析
Drugs R D. 2014 Dec;14(4):301-8. doi: 10.1007/s40268-014-0072-6.
3
Addition of sitagliptin or metformin to insulin monotherapy improves blood glucose control via different effects on insulin and glucagon secretion in hyperglycemic Japanese patients with type 2 diabetes.对于日本2型糖尿病高血糖患者，在胰岛素单药治疗基础上加用西格列汀或二甲双胍，可通过对胰岛素和胰高血糖素分泌产生不同影响来改善血糖控制。
Endocr J. 2015;62(2):133-43. doi: 10.1507/endocrj.EJ14-0148. Epub 2014 Oct 19.
4
Dipeptidyl peptidase-4 inhibitors are effective in Japanese type 2 diabetic patients with sustained endogenous insulin-secreting capacity, a higher body mass index and insulin resistance.二肽基肽酶-4 抑制剂对具有持续内源性胰岛素分泌能力、较高体重指数和胰岛素抵抗的日本 2 型糖尿病患者有效。
J Diabetes Investig. 2013 Mar 18;4(2):190-4. doi: 10.1111/jdi.12016. Epub 2012 Nov 23.
5
Obesity may attenuate the HbA1c-lowering effect of sitagliptin in Japanese type 2 diabetic patients.肥胖可能会减弱西格列汀在日本 2 型糖尿病患者中降低 HbA1c 的作用。
J Diabetes Investig. 2012 Mar 28;3(2):170-4. doi: 10.1111/j.2040-1124.2011.00156.x.
6
Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis.亚洲人与非亚洲人之间二肽基肽酶-4 抑制剂的降糖疗效差异：系统评价和荟萃分析。
Diabetologia. 2013 Apr;56(4):696-708. doi: 10.1007/s00125-012-2827-3. Epub 2013 Jan 24.
7
Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: a randomized controlled trial.在亚洲 2 型糖尿病患者中，加用沙格列汀对比安慰剂联合二甲双胍的疗效和安全性：一项随机对照试验。
Diabetes Res Clin Pract. 2011 Nov;94(2):217-24. doi: 10.1016/j.diabres.2011.07.035. Epub 2011 Aug 26.
8
Predictive clinical parameters for the therapeutic efficacy of sitagliptin in korean type 2 diabetes mellitus.预测西他列汀治疗韩国 2 型糖尿病疗效的临床参数。
Diabetes Metab J. 2011 Apr;35(2):159-65. doi: 10.4093/dmj.2011.35.2.159. Epub 2011 Apr 30.
9
A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes.一项多中心、随机、安慰剂对照、双盲 II 期临床试验，旨在评估 LC 15-0444 在 2 型糖尿病患者中的最佳剂量、疗效和安全性。
Diabetes Obes Metab. 2010 Dec;12(12):1113-9. doi: 10.1111/j.1463-1326.2010.01303.x.
10
Impact of sitagliptin on markers of beta-cell function: a meta-analysis.西他列汀对β细胞功能标志物的影响：一项荟萃分析。
Am J Med Sci. 2009 May;337(5):321-8. doi: 10.1097/MAJ.0b013e31818eb721.

Effects of Sitagliptin on Insulin and Glucagon Levels in Type 2 Diabetes Mellitus.

作者信息

Kim Ji Hyun

机构信息

Division of Endocrinology and Metabolism, Department of Internal Medicine, St. Paul's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.

出版信息

Diabetes Metab J. 2015 Aug;39(4):304-6. doi: 10.4093/dmj.2015.39.4.304.

DOI:10.4093/dmj.2015.39.4.304
PMID:26301191
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4543193/
Abstract
摘要